<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Commonly used options for prevention and treatment of opioid-related side effects in children&lt;sup&gt;[1-3]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Commonly used options for prevention and treatment of opioid-related side effects in children<sup>[1-3]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Commonly used options for prevention and treatment of opioid-related side effects in children<sup>[1-3]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Drug dose or action</td> <td class="subtitle1">Comments</td> </tr> <tr> <td colspan="3"><strong>Constipation</strong></td> </tr> <tr> <td class="indent1">Docusate (solution, 4 or 10 mg/mL or tablet, 50 or 100 mg/tab)</td> <td> <ul> <li>Infants &gt;6 months but &lt;2 years: 12.5 mg orally three times daily </li> <li>Children &gt;2 and adolescents: 40 to 150 mg/day in 1 to 4 divided doses </li> </ul> </td> <td> <p>For prophylaxis of OIC we usually administer 25 to 50 mg twice daily.</p> Not for use in neonates because of benzyl alcohol content.</td> </tr> <tr> <td class="indent1">Senna (syrup, 8.8 mg sennoside/5 mL or tablets, 8.6 mg sennosides/tab)</td> <td> <ul> <li>1 to 2 years: 1.25 to 2.5 mL orally once or twice daily </li> <li>2 to 6 years: 2.5 to 3.75 mL orally once or twice daily </li> <li>6 to 12 years: 5 to 7.5 mL (or 1 to 2 tabs) orally once or twice daily </li> <li>≥12 years: 5 to 15 mL (or 1 to 3 tabs) orally once or twice daily </li> </ul> </td> <td>Usually given once daily at bedtime. Given routinely with docusate for OIC unless contraindicated.</td> </tr> <tr> <td class="indent1">Glycerin suppository</td> <td> <ul> <li>2 to 5 years: 1 pediatric suppository daily </li> <li>≥6 years: 1 adult suppository daily </li> </ul> </td> <td>Usually used as a stimulant in infants. Do not administer suppository if patient is neutropenic.</td> </tr> <tr class="divider_bottom"> <td class="indent1">Polyethylene glycol 3350</td> <td> <ul> <li>0.2 to 0.8 g/kg/day, to a maximum of 17 g orally per day </li> </ul> </td> <td>For constipation unresponsive to above measures</td> </tr> <tr> <td colspan="3"><strong>Nausea/vomiting</strong>*</td> </tr> <tr> <td class="indent1">Ondansetron</td> <td> <ul> <li>0.15 mg/kg IV every 8 hours, usual maximum 4 mg per dose </li> </ul> </td> <td>If this dose inadequate, consider adding another antiemetic</td> </tr> <tr class="divider_bottom"> <td class="indent1">Metoclopramide</td> <td> <ul> <li>0.1 mg/kg IV every 6 to 8 hours as needed, usual maximum 10 mg per dose </li> </ul> </td> <td>Occasionally used as second line drug</td> </tr> <tr> <td colspan="3"><strong>Pruritus</strong>*</td> </tr> <tr> <td class="indent1">Nalbuphine</td> <td> <ul> <li>0.1 mg/kg to a maximum of 5 mg by slow infusion over 20 minutes every 6 hours as needed </li> </ul> </td> <td> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Naloxone</td> <td> <ul> <li>Infusion: 0.25 mcg/kg/hour IV </li> </ul> </td> <td>Usually restricted to patients who are on PCA or continuous infusions of opioid</td> </tr> <tr> <td colspan="3"><strong>Urinary retention</strong></td> </tr> <tr class="divider_bottom"> <td class="indent1">Nalbuphine</td> <td> <ul> <li>0.1 mg/kg to a maximum of 5 mg IV over 20 minutes every 6 hours as needed </li> </ul> </td> <td>Nalbuphine may be helpful in some patients. Bladder catheterization may be necessary for opioid induced urinary retention.</td> </tr> <tr class="divider_bottom"> <td><strong>Excessive sedation</strong></td> <td> <ul> <li>Reduce opioid dose and/or rotate to a different opioid </li> <li>Check for other sedatives concomitantly prescribed </li> <li>Utilize opioid sparing analgesics such as NSAIDs, acetaminophen, regional anesthesia, topical lidocaine </li> </ul> </td> <td> </td> </tr> <tr> <td><strong>Respiratory depression/respiratory arrest</strong></td> <td> <ul> <li>Stop infusion or reduce dose immediately depending on severity </li> <li>Apply physiologic monitors including pulse oximeter </li> <li>If spontaneously breathing, provide oxygen, ensure adequate chest movement/air entry <ul> <li>Administer partial reversal: Naloxone 5 mcg/kg IV every 2 minutes until respiratory rate is age appropriate and patient is responsive </li> </ul> </li> <li>If apneic or breathing inadequately, support ventilation with bag, mask and oxygen <ul> <li>Administer full reversal: Naloxone 10 mcg/kg IV every 2 mins (may administer 0.4 to 2 mg every 2 minutes) until awake and breathing </li> </ul> </li> <li>Observe closely for re-narcotization over an extended time period </li> </ul> </td> <td> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Opioid-related side effects may be reduced by using multimodal opioid sparing analgesic techniques (eg, regional analgesia, nonopioid analgesics, nonpharmacologic analgesic techniques).</div><div class="graphic_footnotes">OIC: opioid induced constipation; IV: intravenous; PCA: patient controlled analgesia.<br/>* Use extreme caution with administration of antihistamines for the treatment of itching, nausea/vomiting, or benzodiazepines for the treatment of nausea/vomiting. Although effective in some patients, these medications are associated with the risk of excessive sedation and respiratory compromise when administered with opioids. If needed, use a reduced dose and administer by the oral route if possible.</div><div class="graphic_reference">References:

<ol>
<li>Maxwell LG, Kaufmann SC, Bitzer S, et al. The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study. Anesth Analg 2005; 100:953. </li>
<li>Malinovsky JM, Lepage JY, Karam G, Pinaud M. Nalbuphine reverses urinary effects of epidural morphine: a case report. J Clin Anesth 2002; 14:535. </li>
<li>Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug-induced urinary retention: incidence, management and prevention. Drug Saf 2008; 31:373.</li>
</ol></div><div id="graphicVersion">Graphic 128150 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
